Jefferies Reaffirms Their Buy Rating on Humana (HUM)
In a report released today, David Windley from Jefferies maintained a Buy rating on Humana, with a price target of $235.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Windley is a 5-star analyst with an average return of 8.6% and a 57.63% success rate. Windley covers the Healthcare sector, focusing on stocks such as Humana, West Pharmaceutical Services, and Centene.
In addition to Jefferies, Humana also received a Buy from Oppenheimer’s Michael Wiederhorn in a report issued today. However, on the same day, Morgan Stanley maintained a Sell rating on Humana (NYSE: HUM).
Based on Humana’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $32.65 billion and a net profit of $195 million. In comparison, last year the company earned a revenue of $29.4 billion and had a net profit of $480 million
Read More on HUM:
Disclaimer & DisclosureReport an Issue
- Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- Humana price target lowered to $195 from $285 at UBS
- Humana price target lowered to $196 from $260 at BofA
- Humana price target lowered to $201 from $290 at Cantor Fitzgerald
- Humana price target lowered to $250 from $310 at Oppenheimer
